Learn more about our portfolio of services and innovative therapies by visiting the product websites or by downloading patient or prescribing information.
Product Information
Our innovative therapies are advancing the treatment of diseases
| Product Monograph | Part III Consumer Information | Websites | |
|---|---|---|---|
| Abraxane® for Injectable Suspension (paclitaxel powder for injectable suspension nanoparticle, albumin-bound (nab®) paclitaxel) | Product Monograph | Part III Consumer Information | |
| Idhifa® (enasidenib tablets) | Product Monograph | Part III Consumer Information | |
| Inrebic® (fedratinib) | Product Monograph | Part III Consumer Information | |
| Istodax® Lyophilized powder for injection (romidepsin for injection) | Product Monograph | Part III Consumer Information | Websites |
| Pomalyst® (pomalidomide capsules) | Product Monograph | Part III Consumer Information | Websites |
| REBLOZYL® (luspatercept for injection) | Product Monograph | Part III Consumer Information | |
| Revlimid® (lenalidomide capsules) | Product Monograph | Part III Consumer Information | Websites |
| Thalomid® (thalidomide capsules House Standard) | Product Monograph | Part III Consumer Information | Websites |
| VIDAZA® (azacitidine for injection) | Product Monograph | Part III Consumer Information | |
| ZEPOSIA® (ozanimod) | Product Monograph | Part III Consumer Information | |
ABRAXANE®, IDHIFA®, INREBIC®, ISTODAX®, POMALYST®, REBLOZYL®, REVLIMID®, THALOMID®, VIDAZA®, ZEPOSIA®, nab® are registered trademarks of Celgene Corporation. IDHIFA® is licensed from Agios Pharmaceuticals. REBLOZYL® is licensed from Acceleron Pharma, Inc. These products may not be approved and/or licensed in all countries where this website is accessible. For information about Celgene products and services in countries other than Canada, please contact the local office (as listed in Global Office Network under About). | |||